VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 25, 2014) -
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Highmark Marketing Inc. (CSE:HMK) ("Highmark") is pleased to announce that it has formed a new business division dedicated to the research and development ("R&D") of proprietary cannabis based products and solutions. Highmark has appointed Dmytro P. Yevtushenko, Ph.D., as Head of the division.
The field of research and development of cannabis and cannabis related products is in its infancy and the company anticipates that the next few years will usher in a number of exciting new developments. While the therapeutic benefits of the compounds contained in cannabis, such as cannabinoids, are only beginning to be understood, the potential global market for these products is large.
Dr. Yevtushenko intends to develop several bioinformatics technology platforms with which to conduct in-house R&D. The focus of the R&D will be to define propagation strategies, advance the understanding and origination of derivative products, and create proprietary strains.
To develop the platforms and conduct the R&D, Dr. Yevtushenko will leverage his extensive knowledge and experience in the field of bioinformatics including: functional genomics, comparative genomics, phylogenetic analysis, protein classification, database searching, sequence alignment, and gene finding.
Highmark intends to pursue the development of these strategic assets for the purpose of commercialization, and is excited about the prospects for its Bioscience division with Dr. Yevtushenko at the helm. We feel that the creation of this division will keep Highmark at the forefront of current scientific trends within the cannabis life sciences sector.
Highmark is a nutraceutical company, based in British Columbia, focused on bringing the health benefits of natural and herbal remedies to the market. Highmark intends to license, distribute and market products in the nutraceutical industry.
Further information about Highmark is available under its profile on the SEDAR website www.sedar.com and on the CSE website http://thecse.ca/CNSX/Securities/Life-Sciences/Highmark-Marketing-Inc.aspx.
The CSE has not reviewed, nor approved or disapproved the content of this press release.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Highmark. Forward-looking information is based on certain key expectations and assumptions made by the management of Highmark, including future plans for acquisitions. Although Highmark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Highmark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Highmark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.